Close Cardiovascular Monitoring during the Early Stages of Treatment for Patients Receiving Immune Checkpoint Inhibitors
<b>Background:</b> There is an unmet medical need for the early detection of immune checkpoint inhibitor (ICI)-induced cardiovascular (CV) adverse events due to a lack of adequate biomarkers. This study aimed to provide insights on the incidence of troponin elevations and echocardiograph...
Saved in:
Main Authors: | Danielle Delombaerde (Author), Christof Vulsteke (Author), Nico Van de Veire (Author), Delphine Vervloet (Author), Veronique Moerman (Author), Lynn Van Calster (Author), Anne-Marie Willems (Author), Lieselot Croes (Author), Félix Gremonprez (Author), Astrid De Meulenaere (Author), Ximena Elzo Kraemer (Author), Kristien Wouters (Author), Marc Peeters (Author), Hans Prenen (Author), Johan De Sutter (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study
by: Danielle Delombaerde, et al.
Published: (2023) -
First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
by: Christof Vulsteke, et al.
Published: (2023) -
Accuracy and precision of fixation locations recorded with the low-cost Eye Tribe tracker in different experimental set-ups
by: Kristien Ooms, et al.
Published: (2015) -
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
by: Diederick J. van Doorn, et al.
Published: (2020) -
Commentary: Artificial Intelligence and Statistics: Just the Old Wine in New Wineskins?
by: Anne A. H. de Hond, et al.
Published: (2022)